Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

被引：5
|
作者：
Elmeliegy, Mohamed [1 ]
Lon, Hoi Kei [1 ]
Wang, Diane [1 ]
Ma, Wei An [1 ]
King, Lindsay [2 ]
Viqueira, Andrea [3 ]
Czibere, Akos [2 ]
机构：
[1] Pfizer, San Diego, CA USA
[2] Pfizer Inc, Cambridge, MA USA
[3] Pfizer SLU, Madrid 28108, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT)
    Venkatesh, Priyanka
    Atrash, Shebli
    Paul, Barry
    Alkharabsheh, Omar
    Afrough, Aimaz
    Mahmoudjafari, Zahra
    Mushtaq, Muhammad Umair
    Hashmi, Hamza
    Davis, James A.
    Abdallah, Al-Ola A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol
    Bahlis, Nizar J.
    Trudel, Suzanne
    Maisel, Christopher
    Lee, Lisa X.
    Monge, Jorge
    Prada, Claudia Paba
    Larson, Sarah M.
    Koehne, Guenther
    Jethava, Yogesh
    Ma, Wei Dong
    De Nicolo, Cristina
    Perez-Cruz, Isabel
    BLOOD, 2023, 142
  • [33] Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
    Tomasson, Michael
    Iida, Shinsuke
    Niesvizky, Ruben
    Mohty, Mohamad
    Bahlis, Nizar J.
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Rodriguez Otero, Paula
    Prince, H. Miles
    Viqueira, Andrea
    Leip, Eric
    Conte, Umberto
    Sullivan, Sharon T.
    Lesokhin, Alexander
    BLOOD, 2023, 142
  • [34] Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma
    Wiedemann, Adam
    Szita, Virag Reka
    Horvath, Robert
    Szederjesi, Attila
    Sebo, Attila
    Toth, Andras David
    Masszi, Tamas
    Varga, Gergely
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [35] Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma
    Munawar, Umair
    Theuersbacher, Johanna
    Steinhardt, Maximilian J.
    Zhou, Xiang
    Han, Seungbin
    Nerreter, Silvia
    Vogt, Cornelia
    Kurian, Shilpa
    Keller, Thorsten
    Regensburger, Ann-Katrin
    Teufel, Eva
    Mersi, Julia
    Bittrich, Max
    Seifert, Franziska
    Haider, Malik S.
    Rasche, Leo
    Hillenkamp, Jost
    Einsele, Hermann
    Kampik, Daniel
    Kortuem, K. Martin
    Waldschmidt, Johannes M.
    HAEMATOLOGICA, 2024, 109 (11) : 3670 - 3680
  • [36] Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review
    Yashar, David
    Regidor, Bernard
    Goldwater, Marissa-Skye
    Bujarski, Sean
    Del Dosso, Ashley
    Berenson, James R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [37] B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma
    Shrestha, Asis
    Alzubi, Marah
    Alrawabdeh, Jawad
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    van Rhee, Frits
    Al Hadidi, Samer
    EJHAEM, 2024, 5 (03): : 554 - 559
  • [38] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.
    Raje, Noopur S.
    Leleu, Xavier P.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Expression of Myeloma Cell and Soluble B-Cell Maturation Antigen (BCMA) in Relapsed and Refractory Multiple Myeloma Patients Treated with GSK2857916 in BMA117159
    Dettman, E. J.
    Rigat, Fabio
    Albert, Josh
    Barnard, Ruth
    Birchler, Mary
    Deghenhardt, Yan
    DeWall, Stephen
    Gaye, Boyenoh
    He, Zangdong
    Liu, Veronica
    Opalinska, Joanna
    BLOOD, 2018, 132
  • [40] Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: analysis of MagnetisMM-3
    Touzeau, Cyrille
    Weisel, Katja
    Bahlis, Nizar
    Quach, Hang
    Hamilton, Finn
    Wang, Shen-wu
    Leip, Eric
    Viqueira, Andrea
    O'Brien, Thomas
    Rodriguez-Otero, Paula
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S82 - S83
12345